Saturday 17 October 2026
Export VIR’s income statement to Excel — free account
Vir Biotechnology, Inc.
Vir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024. In the quarter to June 2026, revenue grew 19,582.5%, EPS grew 160.0% and free cash flow grew 200.5%, each against the same quarter a year earlier. Dividend growth for three consecutive years.
9.96
0.51
−4.87%
Follow VIR
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 10.42 | 6.37 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | 5 | 4 | 5 | 3 | 4 | 4 |
P/S ratio |
0.00 | 14.73 | 47.19 | 41.79 | 4.96 | 2.05 | 16.36 | 13.48 | 12.18 |
Altman Z-Score |
— | — | 1.27 | 8.36 | 8.17 | 5.39 | 2.04 | 1.11 | (0.57) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.07 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | (5.30) | 4.77 | 4.00 | 8.19 | 10.15 | 7.11 | 4.60 | (0.97) |
P/Operating CF |
0.00 | (3.98) | (9.82) | (38.89) | 706.73 | 94.08 | (13.06) | (11.41) | (32.28) |
P/B ratio |
0.00 | 0.00 | 0.90 | 4.45 | 3.80 | 1.59 | 0.89 | 0.87 | 1.09 |
Price to Tangible BV |
0.00 | 0.00 | 1.03 | 4.79 | 3.94 | 1.63 | 0.91 | 0.89 | 1.13 |
EV/Sales |
0.00 | (18.19) | (0.97) | 32.03 | 4.31 | 0.55 | (1.46) | 0.07 | 5.34 |
EV/EBITDA |
0.00 | 1.25 | 0.05 | 0.00 | 11.08 | 1.07 | 0.19 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 1.51 | 0.06 | (12.81) | (99.22) | 0.54 | 0.16 | (0.01) | (0.94) |
EV/FCF |
0.00 | 1.39 | 0.06 | (12.40) | (68.03) | 0.56 | 0.16 | (0.01) | (0.92) |
Quick Ratio |
15.67 | 2.74 | 6.58 | 7.52 | 4.37 | 4.73 | 8.75 | 8.31 | 5.05 |
Current Ratio |
16.00 | 2.95 | 6.81 | 7.80 | 4.58 | 4.93 | 9.05 | 8.71 | 5.54 |
Net Debt/EBITDA |
2.32 | 0.94 | 2.24 | 2.58 | (1.68) | (2.91) | 2.28 | 1.75 | 1.02 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.11 | 0.02 | 0.11 | 0.76 | 0.68 | 0.04 | 0.04 | 0.06 |
Operating CF/Net income |
0.95 | 0.81 | 0.74 | 0.64 | (0.09) | 3.22 | 1.27 | 0.86 | 0.89 |
Capex/Depreciation |
(6.35) | (3.36) | (2.06) | (0.81) | (3.92) | 31.48 | (2.01) | (0.20) | (0.22) |
| 56.33% | 93.39% | (142.74%) | (52.36%) | 49.20% | 29.39% | (33.53%) | (38.09%) | (45.73%) | |
| (31.46%) | (120.97%) | (49.65%) | (41.75%) | 36.80% | 21.69% | (26.06%) | (31.46%) | (36.47%) | |
ROIC |
0.00% | 0.00% | (324.07%) | 0.00% | 36.77% | 0.00% | (783.90%) | (235.77%) | (101.09%) |
Return on Tangible Assets |
(37.76%) | (128.52%) | (48.51%) | (43.21%) | 41.80% | 24.40% | (40.76%) | (52.94%) | (91.84%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 257.60 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
2,308.42% | 939.53% | 1,835.03% | 395.99% | 40.90% | 29.38% | 672.69% | 682.57% | 665.10% |
Selling, General and Administrative Expense of Revenue |
801.07% | 273.07% | 464.69% | 92.89% | 14.68% | 10.01% | 202.41% | 160.41% | 134.30% |
Intangible Assets out of Total Assets |
0.00 | 0.28 | 0.10 | 0.06 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 |
Share Based Compensation of Revenue |
237.56% | 47.37% | 115.39% | 36.14% | 7.65% | 6.32% | 129.17% | 105.73% | 71.58% |
Graham Net Nets |
0.00 | (2.48) | 0.82 | 0.18 | 0.19 | 0.54 | 0.89 | 0.79 | 0.33 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 31.58 | 37.13 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(51.20%) | (111.14%) | (96.28%) | (9.26%) | 9.60% | 15.69% | (43.67%) | (52.04%) | (52.40%) |
Free Cash Flow Yield |
0.00% | (88.60%) | (36.29%) | (6.18%) | (1.28%) | 48.27% | (56.77%) | (45.03%) | (47.45%) |
Revenue per Share |
1.26 | 1.39 | 0.27 | 0.64 | 8.43 | 12.18 | 0.64 | 0.54 | 0.49 |
Operating CF per Share |
(30.85) | (12.27) | (4.27) | (1.60) | (0.37) | 12.54 | (5.81) | (3.28) | (2.83) |
Capex per Share |
(1.27) | (1.07) | (0.29) | (0.05) | (0.17) | (0.51) | (0.16) | (0.03) | (0.03) |
Free Cash Flow per Share |
(32.12) | (13.34) | (4.57) | (1.66) | (0.53) | 12.03 | (5.97) | (3.30) | (2.86) |
Cash per Share |
87.36 | 14.25 | 12.84 | 6.25 | 5.52 | 18.21 | 11.45 | 7.30 | 3.39 |
Shareholders Equity per Share |
0.00 | (23.37) | 13.97 | 6.02 | 11.02 | 15.67 | 11.86 | 8.44 | 5.52 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | (23.37) | 13.97 | 6.02 | 11.02 | 15.67 | 11.86 | 8.44 | 5.52 |
Free Cash Flow |
(69.12) | (102.26) | (138.57) | (197.31) | (69.41) | 1,595.25 | (800.36) | (450.28) | (396.36) |
Working Capital |
180.00 | 77.88 | 343.79 | 673.30 | 1,221.58 | 2,008.05 | 1,412.82 | 922.80 | 421.27 |
Capital Expenditures |
(2.74) | (8.17) | (8.94) | (6.37) | (21.82) | (68.01) | (21.57) | (3.93) | (4.58) |
Net Current Asset Value |
192.00 | (252.99) | 314.87 | 570.46 | 1,040.40 | 1,794.95 | 1,259.40 | 794.03 | 276.53 |
EV/EBIT |
0.00 | 1.22 | 0.04 | 0.00 | 11.22 | 1.07 | 0.18 | 0.00 | 0.00 |
Capex to Sales |
1.01 | 0.77 | 1.10 | 0.08 | 0.02 | 0.04 | 0.25 | 0.05 | 0.07 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 12.93 | 3.97 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.09 | 0.20 | 0.27 | 0.44 | 0.13 | (0.02) | 0.11 | 0.32 | 0.38 |
Cash ROIC |
(36.77%) | 146.15% | (17.03%) | (13.50%) | (3.23%) | 35.51% | (25.60%) | (20.99%) | (32.11%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 11.36 | 22.61 | 0.43 | 0.15 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 36.14 | 16.02 | 836.13 | 2,194.75 | 137,619.04 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
5.50 | 5.74 | 6.18 | 5.48 | 5.80 | 6.47 | 6.38 | 5.71 | 7.44 |
Average Assets |
222.00 | 95.80 | 351.83 | 715.42 | 1,436.51 | 2,378.18 | 2,360.57 | 1,658.94 | 1,200.82 |
Average Common Equity |
(124.00) | (124.09) | 122.38 | 570.40 | 1,074.35 | 1,754.91 | 1,834.10 | 1,370.31 | 957.83 |
Columns are period end dates